Functional assessment tools in children with Pompe disease

A pilot comparative study to identify suitable outcome measures for the standard of care

Federica Ricci, Chiara Brusa, Francesca Rossi, Enrica Rolle, Valeria Placentino, Angela Berardinelli, Veronica Pagliardini, Francesco Porta, Marco Spada, Tiziana Mongini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Pompe disease (PD) is a rare condition caused by mutations in gene encoding for the enzyme alpha-glucosidase, resulting in an abnormal intracellular accumulation of glycogen. The disease clinical spectrum ranges from severe infantile forms to adult-onset forms with minor limitations. Since 2000 enzyme replacement therapy (ERT) is available and disease natural history has changed, with prolonged survival and evidence of myopathic features. Methods: In this study, we monitored disease progression up to three years in eight young patients with PD. Based on the literature data and the long term personal experience, we selected validated functional scales for neuromuscular disorders and compared the results to identify a simple and reliable protocol for the follow-up of children with PD. Moreover, we evaluated cognitive functions using developmental/cognitive tests. Results: Based on study results, we suggest that motor functions in children with PD could be better assessed by Chop Intend, MFM20 (Motor Function Measure Scale for Neuromuscular Diseases 20) and NSAA (North Star Ambulatory Assessment), according to age and functional level. Evaluation should be completed with ROM (Range Of Motion) measurement, MRC (Medical Research Council) evaluation and 6MWT (6 Minute Walk test) when possible. Conclusions: The proposed protocol seems to be reliable and should be done every six months, because of the progressive natural history of the disease, the rapid changes typical of developmental age and the need to document ERT effects. About cognitive functions, additional tests to classical intelligence scales (WISC, WPPSI) should be useful to better describe specific neuropsychological profile.

Original languageEnglish
Pages (from-to)1103-1109
Number of pages7
JournalEuropean Journal of Paediatric Neurology
Volume22
Issue number6
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Glycogen Storage Disease Type II
Standard of Care
Outcome Assessment (Health Care)
Enzyme Replacement Therapy
Cognition
Neuromuscular Diseases
alpha-Glucosidases
Articular Range of Motion
Natural History
Glycogen
Intelligence
Disease Progression
Biomedical Research
Mutation
Survival
Enzymes
Genes

Keywords

  • Children
  • Cognitive evaluation
  • Emerging phenotype
  • Motor function
  • Outcome measures
  • Pompe disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Functional assessment tools in children with Pompe disease : A pilot comparative study to identify suitable outcome measures for the standard of care. / Ricci, Federica; Brusa, Chiara; Rossi, Francesca; Rolle, Enrica; Placentino, Valeria; Berardinelli, Angela; Pagliardini, Veronica; Porta, Francesco; Spada, Marco; Mongini, Tiziana.

In: European Journal of Paediatric Neurology, Vol. 22, No. 6, 01.11.2018, p. 1103-1109.

Research output: Contribution to journalArticle

Ricci, Federica ; Brusa, Chiara ; Rossi, Francesca ; Rolle, Enrica ; Placentino, Valeria ; Berardinelli, Angela ; Pagliardini, Veronica ; Porta, Francesco ; Spada, Marco ; Mongini, Tiziana. / Functional assessment tools in children with Pompe disease : A pilot comparative study to identify suitable outcome measures for the standard of care. In: European Journal of Paediatric Neurology. 2018 ; Vol. 22, No. 6. pp. 1103-1109.
@article{8a5d8df2650c4fd2a3d719bd5e47a245,
title = "Functional assessment tools in children with Pompe disease: A pilot comparative study to identify suitable outcome measures for the standard of care",
abstract = "Background: Pompe disease (PD) is a rare condition caused by mutations in gene encoding for the enzyme alpha-glucosidase, resulting in an abnormal intracellular accumulation of glycogen. The disease clinical spectrum ranges from severe infantile forms to adult-onset forms with minor limitations. Since 2000 enzyme replacement therapy (ERT) is available and disease natural history has changed, with prolonged survival and evidence of myopathic features. Methods: In this study, we monitored disease progression up to three years in eight young patients with PD. Based on the literature data and the long term personal experience, we selected validated functional scales for neuromuscular disorders and compared the results to identify a simple and reliable protocol for the follow-up of children with PD. Moreover, we evaluated cognitive functions using developmental/cognitive tests. Results: Based on study results, we suggest that motor functions in children with PD could be better assessed by Chop Intend, MFM20 (Motor Function Measure Scale for Neuromuscular Diseases 20) and NSAA (North Star Ambulatory Assessment), according to age and functional level. Evaluation should be completed with ROM (Range Of Motion) measurement, MRC (Medical Research Council) evaluation and 6MWT (6 Minute Walk test) when possible. Conclusions: The proposed protocol seems to be reliable and should be done every six months, because of the progressive natural history of the disease, the rapid changes typical of developmental age and the need to document ERT effects. About cognitive functions, additional tests to classical intelligence scales (WISC, WPPSI) should be useful to better describe specific neuropsychological profile.",
keywords = "Children, Cognitive evaluation, Emerging phenotype, Motor function, Outcome measures, Pompe disease",
author = "Federica Ricci and Chiara Brusa and Francesca Rossi and Enrica Rolle and Valeria Placentino and Angela Berardinelli and Veronica Pagliardini and Francesco Porta and Marco Spada and Tiziana Mongini",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.ejpn.2018.08.001",
language = "English",
volume = "22",
pages = "1103--1109",
journal = "European Journal of Paediatric Neurology",
issn = "1090-3798",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Functional assessment tools in children with Pompe disease

T2 - A pilot comparative study to identify suitable outcome measures for the standard of care

AU - Ricci, Federica

AU - Brusa, Chiara

AU - Rossi, Francesca

AU - Rolle, Enrica

AU - Placentino, Valeria

AU - Berardinelli, Angela

AU - Pagliardini, Veronica

AU - Porta, Francesco

AU - Spada, Marco

AU - Mongini, Tiziana

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: Pompe disease (PD) is a rare condition caused by mutations in gene encoding for the enzyme alpha-glucosidase, resulting in an abnormal intracellular accumulation of glycogen. The disease clinical spectrum ranges from severe infantile forms to adult-onset forms with minor limitations. Since 2000 enzyme replacement therapy (ERT) is available and disease natural history has changed, with prolonged survival and evidence of myopathic features. Methods: In this study, we monitored disease progression up to three years in eight young patients with PD. Based on the literature data and the long term personal experience, we selected validated functional scales for neuromuscular disorders and compared the results to identify a simple and reliable protocol for the follow-up of children with PD. Moreover, we evaluated cognitive functions using developmental/cognitive tests. Results: Based on study results, we suggest that motor functions in children with PD could be better assessed by Chop Intend, MFM20 (Motor Function Measure Scale for Neuromuscular Diseases 20) and NSAA (North Star Ambulatory Assessment), according to age and functional level. Evaluation should be completed with ROM (Range Of Motion) measurement, MRC (Medical Research Council) evaluation and 6MWT (6 Minute Walk test) when possible. Conclusions: The proposed protocol seems to be reliable and should be done every six months, because of the progressive natural history of the disease, the rapid changes typical of developmental age and the need to document ERT effects. About cognitive functions, additional tests to classical intelligence scales (WISC, WPPSI) should be useful to better describe specific neuropsychological profile.

AB - Background: Pompe disease (PD) is a rare condition caused by mutations in gene encoding for the enzyme alpha-glucosidase, resulting in an abnormal intracellular accumulation of glycogen. The disease clinical spectrum ranges from severe infantile forms to adult-onset forms with minor limitations. Since 2000 enzyme replacement therapy (ERT) is available and disease natural history has changed, with prolonged survival and evidence of myopathic features. Methods: In this study, we monitored disease progression up to three years in eight young patients with PD. Based on the literature data and the long term personal experience, we selected validated functional scales for neuromuscular disorders and compared the results to identify a simple and reliable protocol for the follow-up of children with PD. Moreover, we evaluated cognitive functions using developmental/cognitive tests. Results: Based on study results, we suggest that motor functions in children with PD could be better assessed by Chop Intend, MFM20 (Motor Function Measure Scale for Neuromuscular Diseases 20) and NSAA (North Star Ambulatory Assessment), according to age and functional level. Evaluation should be completed with ROM (Range Of Motion) measurement, MRC (Medical Research Council) evaluation and 6MWT (6 Minute Walk test) when possible. Conclusions: The proposed protocol seems to be reliable and should be done every six months, because of the progressive natural history of the disease, the rapid changes typical of developmental age and the need to document ERT effects. About cognitive functions, additional tests to classical intelligence scales (WISC, WPPSI) should be useful to better describe specific neuropsychological profile.

KW - Children

KW - Cognitive evaluation

KW - Emerging phenotype

KW - Motor function

KW - Outcome measures

KW - Pompe disease

UR - http://www.scopus.com/inward/record.url?scp=85052628127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052628127&partnerID=8YFLogxK

U2 - 10.1016/j.ejpn.2018.08.001

DO - 10.1016/j.ejpn.2018.08.001

M3 - Article

VL - 22

SP - 1103

EP - 1109

JO - European Journal of Paediatric Neurology

JF - European Journal of Paediatric Neurology

SN - 1090-3798

IS - 6

ER -